Anebulo Pharmaceuticals Stock Price, News & Analysis

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) is a clinical-stage pharmaceutical company focused on developing drug candidates for people suffering from cannabis-induced toxicity and acute cannabinoid-induced toxic effects. According to the company’s public disclosures, Anebulo is advancing a lead product candidate called selonabant (ANEB-001), which is being developed as a specific antidote for acute cannabis-induced toxicity, including acute cannabinoid intoxication in adults and cannabis poisoning in pediatric subjects.

The company describes selonabant as a potent, small molecule antagonist of the cannabinoid receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabis and certain other cannabinoids. Anebulo reports that selonabant has completed a Phase 2 proof-of-concept clinical trial in healthy adults challenged with oral delta-9-tetrahydrocannabinol (THC). In that study, oral selonabant was observed to block or reverse key central nervous system (CNS) effects of THC and was well tolerated, with no serious adverse events reported. An open-label extension of the trial evaluated higher THC challenge doses alongside selonabant, and the company states that treatment-related adverse events were mild and transient.

A key element of Anebulo’s strategy, based on its announcements, is the prioritization of an intravenous (IV) formulation of selonabant. Rather than proceeding directly with Phase 3 studies of the oral formulation in adults with acute cannabinoid intoxication, the company is focusing on IV selonabant as a potential treatment for pediatric patients with acute cannabis-induced toxicity. Anebulo has stated that it believes pediatric cannabis toxicity can be more serious than in adults and that an IV formulation may offer the potential for a faster timeline to approval relative to the adult oral product.

The company reports that it has scaled up the IV formulation of selonabant for initial clinical safety studies and initiated a Phase 1 single ascending dose (SAD) study of IV selonabant in healthy adult subjects. This randomized, double-blind, placebo-controlled study is designed to investigate the safety, tolerability, and pharmacokinetics of intravenously administered selonabant in young adults. Anebulo notes that this study design was cleared by the U.S. Food and Drug Administration (FDA) and that the study is supported in part by a collaborative grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH).

In its public communications, Anebulo emphasizes the unmet medical need for an emergency antidote to acute cannabis-induced toxicity, particularly in children. The company cites concerns that acute cannabis exposure in pediatric patients can lead to serious and potentially life-threatening consequences, including CNS depression, respiratory depression, coma, and, in rare cases, death. It also references research indicating that children may be more sensitive to the toxic effects of cannabis due in part to age-related differences in the abundance and distribution of cannabis receptors in the brain, which can increase the risk of hospitalization and intensive care admission.

Anebulo’s development program also includes an observational study in patients presenting to emergency departments with cannabis toxicity. The company states that this study is intended to determine concentrations of cannabinoids and metabolites in plasma and to gather information on signs and symptoms, treatment, and patient disposition, including hospital and intensive care unit admission. Anebulo has indicated that this study is being amended to focus more specifically on pediatric patients.

From an intellectual property perspective, Anebulo reports that selonabant is protected by issued U.S. patents and additional patent applications. These include patents covering various methods of use of the compound and, in some disclosures, the composition of matter of the crystalline form of selonabant, as well as pending applications related to methods of use and delivery systems. The company highlights this patent estate as part of its strategy to support the development of selonabant for acute cannabis-induced toxicity in both adults and children.

Anebulo describes itself as a single-segment business focused on the development of selonabant and related clinical and regulatory activities. The company has reported receiving grant funding from NIDA to support its IV selonabant program and has also disclosed private placement financings and a loan agreement to fund its research and development activities. These financings, together with grant support, are presented by the company as resources for advancing its clinical studies and regulatory interactions.

In addition to its drug development activities, Anebulo has publicly discussed a strategic review and going private process. The company announced that a Special Committee of independent directors and its Board of Directors approved, as part of a proposed going private transaction, a reverse stock split structure intended to reduce the number of record holders and enable termination of its registration as an SEC reporting company and delisting from The Nasdaq Stock Market. Subsequent disclosures and an 8-K filing indicate that the Board decided to abandon the reverse stock split and instead pursue a voluntary self-tender offer to purchase a specified number of shares at a stated cash price per share, with the tender offer described as part of the company’s plan to go private by maintaining its number of stockholders below 300.

Across its press releases and SEC filings, Anebulo consistently characterizes its core focus as the development of selonabant as a targeted therapy for rapidly reversing key symptoms of acute cannabis-induced toxicity. Its public statements emphasize collaboration with regulators such as FDA, support from NIDA, and an ongoing clinical and observational program aimed at addressing what it describes as a significant and growing unmet need in pediatric and adult cannabis toxicity.